​

Zentalis Pharmaceuticals Stock (NASDAQ:ZNTL)

ForecastOwnershipFinancialsChart

Previous Close

$4.45

52W Range

$1.21 - $6.95

50D Avg

$4.16

200D Avg

$2.86

Market Cap

$308.24M

Avg Vol (3M)

$1.17M

Beta

1.93

Div Yield

-

ZNTL Company Profile

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

106

IPO Date

Apr 03, 2020

Website

ZNTL Performance

ZNTL Financial Summary

Dec 25Dec 24Dec 23
Revenue-$67.42M-
Operating Income$-152.81M$-191.19M$-299.51M
Net Income$-137.06M$-165.84M$-292.19M
EBITDA$-152.81M$-186.17M$-247.60M
Basic EPS$-1.91$-2.33$-4.47
Diluted EPS$-1.91$-2.33$-4.47

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
WHWKWhitehawk Therapeutics Inc
ARTVArtiva Biotherapeutics, Inc.
ALXOALX Oncology Holdings Inc.
STROSutro Biopharma, Inc.
PLRXPliant Therapeutics, Inc.
DTILPrecision BioSciences, Inc.
TILInstil Bio, Inc.
IMMXImmix Biopharma, Inc.
MGNXMacroGenics, Inc.
STTKShattuck Labs, Inc.